News
AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...
An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...
2don MSN
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
1d
Zacks.com on MSNAstrazeneca (AZN) Outpaces Stock Market Gains: What You Should KnowThe most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse ...
Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...
2d
GlobalData on MSNAstraZeneca and Pangaea partner for AI detection of hypophosphatasiaAstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...
AstraZeneca (LSE:AZN) recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on ...
3d
Pharmaceutical Technology on MSNEC approves AstraZeneca’s acalabrutinib combo for CLLThis trial demonstrated that 77% of subjects treated with Calquence and venetoclax combo and 83% of those who received the ...
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...
Astrazeneca unveiled overhaul of its manufacturing and supply operations driven by deep tech and AI at London Tech Week.
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results